NeuroScientific Biopharmaceuticals (ASX:NSB) has announced positive results of its lead drug candidate EmtinB™ in a gold standard animal model of Multiple Sclerosis.
The study evaluated EmtinB™ across three dose groups, including 10mg/kg and 20mg/kg dosed daily, and an exploratory group of 40mg/kg dosed once every 3 days.
The results of the study suggest EmtinB™ is a neuroprotective agent and treatment for neurodegenerative diseases, such as Multiple Sclerosis, with a likely target therapeutic dose range of 10-20mg/kg in a mouse (equivalent to an adult human dose range of 50mg to 115mg).
Following the announcement, shares of Neuroscientific Biopharmaceuticals were unchanged at $0.097.